Lonsurf (Trifluridine / Tipiracil)

Trifluridine-tipiracil (Lonsurf) is a cancer medicine used for colon or rectal cancer and stomach cancer that has spread and was already treated with other medicines. It is taken by mouth as pills. It works by getting into the cancer cells' DNA so they cannot copy themselves and grow.

Brand names:Lonsurf
Medication

What people taking Lonsurf (Trifluridine / Tipiracil) report

Every report comes from a Lived member, sent anonymously.

Have you tried Lonsurf (Trifluridine / Tipiracil) for Colorectal Cancer?

NameHow it went

About Lonsurf (Trifluridine / Tipiracil)

What It's For

Lonsurf is a chemotherapy tablet that combines two medicines, trifluridine and tipiracil. It is approved for adults with cancer that has spread (metastatic cancer) in two situations, both after other treatments have already been used. The first is metastatic colorectal cancer that has already been treated with the standard chemotherapy drugs for this cancer (a fluoropyrimidine such as fluorouracil, oxaliplatin and irinotecan), a biologic drug that blocks tumor blood vessel growth, and, for tumors without a change in the RAS genes (genes that drive cell growth), a drug that blocks EGFR (epidermal growth factor receptor), a growth signal on cancer cells. For colorectal cancer, Lonsurf can be taken alone or together with bevacizumab (Avastin), an infusion that limits the blood supply tumors need. The second is metastatic adenocarcinoma of the stomach or of the gastroesophageal junction, where the esophagus meets the stomach, after at least two earlier lines of chemotherapy. For stomach cancer it is used on its own. In these situations the goal is to slow the cancer and extend life while keeping daily life as manageable as possible, not to cure the cancer.

How It Works

Cancer cells divide quickly, and each division requires copying the cell's DNA, its genetic material. Trifluridine closely resembles thymidine, one of the natural building blocks of DNA. Once inside a cancer cell, it is built into the DNA in place of thymidine, which disrupts DNA copying and stops the cell from multiplying. On its own, trifluridine taken by mouth would be broken down quickly by an enzyme called thymidine phosphorylase. Tipiracil blocks that enzyme, so more trifluridine stays in the bloodstream long enough to reach the tumor. Tipiracil does not attack cancer itself; its job is to make trifluridine work as a pill. Because trifluridine also affects healthy cells that divide quickly, especially in the bone marrow, it lowers blood counts, which explains its most important side effects.

Dosage & Administration

Lonsurf is taken by mouth twice a day with food, at around the same times each day, on a set schedule within a 28-day (four-week) cycle: five days on and two days off for two weeks (days 1 to 5 and 8 to 12), then about two weeks with no tablets. The cycle then repeats for as long as the cancer stays under control and side effects remain manageable. The dose is calculated from body size (body surface area), and the tablets come in two strengths, so a person may take a mix of both to reach the right amount. Tablets are swallowed whole. If a dose is missed or vomited, do not take it again; take the next scheduled dose as planned. Lonsurf is a cytotoxic drug, meaning it kills cells. Anyone else who handles the tablets, such as a caregiver, should wear gloves, and leftover tablets should be returned or disposed of as the pharmacy instructs. Doses are often paused or lowered when blood counts drop or side effects become severe; once lowered, they are not raised again.

Side Effects

Low blood counts are the most common and most important effect. In clinical trials, about 4 in 10 people taking Lonsurf alone developed a severely low neutrophil count (neutrophils are the white blood cells that fight bacterial infection), and the rate was about half of people when it was combined with bevacizumab. Anemia (low red blood cells) can cause tiredness and shortness of breath, and low platelets can make bruising or bleeding easier. A small number of people in the trials died of infections that took hold while their counts were low. For this reason, blood counts are checked before each cycle starts and again around day 15. Contact the care team right away for a fever or other signs of infection, such as chills or body aches. Many oncology teams give a specific temperature to call about and an after-hours number to use. Other common effects are fatigue, nausea, loss of appetite, diarrhea, vomiting and abdominal pain. These are often manageable with anti-nausea and anti-diarrhea medicines, but severe or persistent nausea, vomiting, diarrhea or abdominal pain should be reported to the care team rather than waited out. Some people also notice hair loss, mouth sores or changes in taste.

Interactions & Warnings

Lonsurf can harm a developing baby. Pregnancy status is checked before starting in anyone who could become pregnant. Women who could become pregnant should use effective birth control during treatment and for at least 6 months after the last dose, and men with a partner who could become pregnant should use condoms during treatment and for at least 3 months after the last dose. Tell the care team promptly about a known or suspected pregnancy. Breastfeeding is not recommended during treatment and for 1 day after the final dose. Liver and kidney function matter. Lonsurf is not started in people with moderate or severe liver impairment, and the dose is reduced for people with severe kidney impairment. The prescribing information does not list specific drug interactions. Even so, the oncology team and pharmacist should know about every other medicine and supplement being taken.

What to Expect

Treatment follows a rhythm of two weeks with tablets and two weeks without, with blood tests at least twice per cycle and regular visits to check how the cancer and side effects are doing. Fatigue and low counts often build over successive cycles, and dose delays or reductions are a normal part of keeping treatment going rather than a sign that it has failed. In the trials that led to approval, Lonsurf extended survival by a modest but real margin. In previously treated colorectal cancer, median survival was about 7 months with Lonsurf compared with about 5 months with placebo. When bevacizumab was added in a later trial, median survival was about 11 months compared with about 7.5 months for Lonsurf alone. In previously treated stomach cancer, median survival was about 6 months compared with about 3.5 months with placebo. A median is the midpoint, so some people do considerably better and others less well. Treatment usually continues until the cancer grows again or side effects outweigh the benefit. Decisions about continuing, switching or stopping in favor of comfort-focused care are made together with the oncology team.

Questions to Ask Your Doctor

  1. 1.What do you expect Lonsurf to do for my cancer, and how will we know if it is working?
  2. 2.Would adding bevacizumab make sense for me, and what extra risks would that bring?
  3. 3.At what temperature or symptoms should I call, and how do I reach the team after hours?
  4. 4.How will we handle low blood counts, fatigue or diarrhea if they start to interfere with treatment?
  5. 5.What other options are available if Lonsurf stops working or I cannot tolerate it?

Last reviewed • Oct 2026

Educational content, not medical advice.